As Part of Year-Long Restructuring, Transgenomic To Sell or Shutter Scottish Nucleic Acids Facility | GenomeWeb

Transgenomic, surpassing the one-year mark on its ongoing corporate makeover, continues to move away from nucleotide consumables as it disclosed plans last week to "either sell or liquidate" the last remaining vestige of its nucleic acids business.

"This is something that for the past year we've been talking publicly quite a lot about: Focusing on our biosystems business is really what we think is our key area of opportunity going forward," Rob Pogulis, Transgenomic director of strategic planning, told Pharmacogenomics Reporter this week.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.

In Science this week: metagenomic-based technique for determining protein structure, and more.

An academic laments the rise of narcissism in the sciences, the Guardian reports.

Outgoing FDA commissioner Robert Califf writes in an editorial that the agency can help boost innovation.

The Trump transition team has asked NIH Director Francis Collins to remain at his post, though it's unclear for how long that will be.